{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:04:27Z","timestamp":1789261467241,"version":"build-2803163510"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:p>This Viewpoint discusses the potential promise of the therapeutic use of psychedelics for mental illness and substance use disorders, acknowledging many open research questions and unique challenges with these substances.<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2023.1968","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:41:09Z","timestamp":1690378869000},"page":"979","source":"Crossref","is-referenced-by-count":28,"title":["Psychedelics as Therapeutics\u2014Potential and Challenges"],"prefix":"10.1001","volume":"80","author":[{"given":"Nora D.","family":"Volkow","sequence":"first","affiliation":[{"name":"National Institute on Drug Abuse, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Gordon","sequence":"additional","affiliation":[{"name":"National Institute of Mental Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Wargo","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6633","key":"yvp230021r1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"issue":"18","key":"yvp230021r2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"yvp230021r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104793","article-title":"Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review.","volume":"140","author":"van Elk","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"yvp230021r4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1076459","article-title":"Serotonergic psychedelics for depression: what do we know about neurobiological mechanisms of action?","volume":"13","author":"Husain","year":"2023","journal-title":"Front Psychiatry"},{"issue":"2","key":"yvp230021r6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects.","volume":"4","author":"Yaden","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"yvp230021r7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects.","volume":"4","author":"Olson","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"17","key":"yvp230021r8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"yvp230021r9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/13634615221100385","article-title":"Modalities of the psychedelic experience: microclimates of set and setting in hallucinogen research and culture.","volume":"59","author":"Hartogsohn","year":"2022","journal-title":"Transcult Psychiatry"},{"issue":"10","key":"yvp230021r10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns.","volume":"7","author":"Anderson","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"yvp230021r5","unstructured":"Goldhill? O. Largest psilocybin trial finds the psychedelic is effective in treating serious depression. STAT News. November 9, 2021. Accessed May 15, 2023. https:\/\/www.statnews.com\/2021\/11\/09\/largest-psilocybin-trial-finds-psychedelic-effective-treating-serious-depression\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2807608\/jamapsychiatry_volkow_2023_vp_230021_1696256864.50808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:04:40Z","timestamp":1696417480000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2807608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1968","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}